Welcome to our dedicated page for Nasus Pharma news (Ticker: NSRX), a resource for investors and traders seeking the latest updates and insights on Nasus Pharma stock.
Nasus Pharma Ltd. (NSRX) is a clinical-stage pharmaceutical company whose news flow centers on the development of intranasal powder products for acute and emergency medical conditions. As a NYSE American–listed issuer and foreign private filer, the company regularly releases updates that are of interest to investors following emerging healthcare and drug delivery platforms.
News about Nasus Pharma frequently highlights progress in its lead program, NS002, an investigational intranasal epinephrine powder formulation being developed as a needle-free alternative to epinephrine autoinjectors for anaphylaxis. Coverage includes early clinical trial results, regulatory milestones such as Health Canada authorization for a Phase 2 study, and announcements related to dosing of participants and study design details.
Company press releases also address corporate and capital markets events. These include the pricing and closing of its initial public offering, the approval and commencement of trading of its ordinary shares on the NYSE American under the symbol NSRX, and ceremonial milestones such as ringing the closing bell at the New York Stock Exchange. Such items provide context on Nasus Pharma’s transition to the public markets and its stated use of proceeds to advance the intranasal epinephrine program and general corporate activities.
In addition, Nasus Pharma issues news on strategic collaborations and leadership changes. Announcements have described expanded agreements with Aptar France S.A.S. and AptarGroup, Inc. to support development and planned commercialization of NS002 through device technology, development services, and supply arrangements. Leadership updates, such as the appointment of an Executive Vice President and Chief Financial Officer, are also disclosed, along with shareholder communications like the CEO’s letter outlining clinical, regulatory, and corporate priorities.
Investors and observers who follow NSRX news can use this page to review company press releases and related coverage that track Nasus Pharma’s clinical development, regulatory interactions, collaborations, governance developments, and capital markets activities over time.
Nasus Pharma (NYSE:NSRX), a clinical-stage pharmaceutical company specializing in intranasal emergency medical treatments, has announced the pricing of its Initial Public Offering (IPO). The company is offering 1,250,000 ordinary shares at $8.00 per share, aiming to raise $10 million in gross proceeds.
The company has granted underwriters a 45-day option to purchase up to 187,500 additional shares. Trading will commence on NYSE American LLC on August 13, 2025, under the symbol "NSRX". The proceeds will primarily fund the development of their intranasal Epinephrine program, including manufacturing scale-up and Phase 2 studies.